A comparison between warfarin and apixaban: A patient's perspective
BACKGROUND: Novel oral anticoagulants (NOACs) were developed as alternatives to warfarin. However, the patients' preference regarding warfarin or the NOACs has not been established. Quality-of-life (QOL) surveys are a well-established method for determining the patients' preference for a t...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Annals of Thoracic Medicine |
Subjects: | |
Online Access: | http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=2;spage=84;epage=89;aulast=Althemery |
id |
doaj-d8d282c68e044e52bbf557df6a0052c7 |
---|---|
record_format |
Article |
spelling |
doaj-d8d282c68e044e52bbf557df6a0052c72020-11-25T02:27:38ZengWolters Kluwer Medknow PublicationsAnnals of Thoracic Medicine1817-17371998-35572020-01-01152848910.4103/atm.ATM_352_19A comparison between warfarin and apixaban: A patient's perspectiveAbdullah U AlthemeryAbdullah A AlfaifiAbdulrahman AlturaikiMaha A. L. AmmariKhizra SultanaLeanne LaiBACKGROUND: Novel oral anticoagulants (NOACs) were developed as alternatives to warfarin. However, the patients' preference regarding warfarin or the NOACs has not been established. Quality-of-life (QOL) surveys are a well-established method for determining the patients' preference for a treatment route. AIMS: This study compared the patients' perspectives on treatment with warfarin versus apixaban using the QOL measures. SETTINGS AND DESIGN: This cross-sectional study was conducted in 2019 for patients treated with either warfarin or apixaban at King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia. METHODS: We used a series of descriptive statistics to examine the differences in sociodemographic characteristics among patients. A propensity score-matching approach was employed to reduce the effect of confounding variables that often influence treatment selection. Greedy matching approach was used to analyze the QOL. RESULTS: A total of 388 patients were identified, of which 124 were matched between the two groups (62 patients in each group). Most of the patients were female, married, below the sufficiency level, educated, and nonsmokers. The patients using warfarin had a significantly better health state (M = 69.64, standard deviation [SD] = 16.52) than those using apixaban (M = 66.33, SD = 23.17), P = 0.011. CONCLUSIONS: Future studies should explore why patients using apixaban showed lower QOL scores and improve health-care providers' awareness of these issues.http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=2;spage=84;epage=89;aulast=Althemeryapixabaneuroqoloral anticoagulantspatient-reported outcomespropensity score matchingwarfarin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Abdullah U Althemery Abdullah A Alfaifi Abdulrahman Alturaiki Maha A. L. Ammari Khizra Sultana Leanne Lai |
spellingShingle |
Abdullah U Althemery Abdullah A Alfaifi Abdulrahman Alturaiki Maha A. L. Ammari Khizra Sultana Leanne Lai A comparison between warfarin and apixaban: A patient's perspective Annals of Thoracic Medicine apixaban euroqol oral anticoagulants patient-reported outcomes propensity score matching warfarin |
author_facet |
Abdullah U Althemery Abdullah A Alfaifi Abdulrahman Alturaiki Maha A. L. Ammari Khizra Sultana Leanne Lai |
author_sort |
Abdullah U Althemery |
title |
A comparison between warfarin and apixaban: A patient's perspective |
title_short |
A comparison between warfarin and apixaban: A patient's perspective |
title_full |
A comparison between warfarin and apixaban: A patient's perspective |
title_fullStr |
A comparison between warfarin and apixaban: A patient's perspective |
title_full_unstemmed |
A comparison between warfarin and apixaban: A patient's perspective |
title_sort |
comparison between warfarin and apixaban: a patient's perspective |
publisher |
Wolters Kluwer Medknow Publications |
series |
Annals of Thoracic Medicine |
issn |
1817-1737 1998-3557 |
publishDate |
2020-01-01 |
description |
BACKGROUND: Novel oral anticoagulants (NOACs) were developed as alternatives to warfarin. However, the patients' preference regarding warfarin or the NOACs has not been established. Quality-of-life (QOL) surveys are a well-established method for determining the patients' preference for a treatment route.
AIMS: This study compared the patients' perspectives on treatment with warfarin versus apixaban using the QOL measures.
SETTINGS AND DESIGN: This cross-sectional study was conducted in 2019 for patients treated with either warfarin or apixaban at King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.
METHODS: We used a series of descriptive statistics to examine the differences in sociodemographic characteristics among patients. A propensity score-matching approach was employed to reduce the effect of confounding variables that often influence treatment selection. Greedy matching approach was used to analyze the QOL.
RESULTS: A total of 388 patients were identified, of which 124 were matched between the two groups (62 patients in each group). Most of the patients were female, married, below the sufficiency level, educated, and nonsmokers. The patients using warfarin had a significantly better health state (M = 69.64, standard deviation [SD] = 16.52) than those using apixaban (M = 66.33, SD = 23.17), P = 0.011.
CONCLUSIONS: Future studies should explore why patients using apixaban showed lower QOL scores and improve health-care providers' awareness of these issues. |
topic |
apixaban euroqol oral anticoagulants patient-reported outcomes propensity score matching warfarin |
url |
http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=2;spage=84;epage=89;aulast=Althemery |
work_keys_str_mv |
AT abdullahualthemery acomparisonbetweenwarfarinandapixabanapatientsperspective AT abdullahaalfaifi acomparisonbetweenwarfarinandapixabanapatientsperspective AT abdulrahmanalturaiki acomparisonbetweenwarfarinandapixabanapatientsperspective AT mahaalammari acomparisonbetweenwarfarinandapixabanapatientsperspective AT khizrasultana acomparisonbetweenwarfarinandapixabanapatientsperspective AT leannelai acomparisonbetweenwarfarinandapixabanapatientsperspective AT abdullahualthemery comparisonbetweenwarfarinandapixabanapatientsperspective AT abdullahaalfaifi comparisonbetweenwarfarinandapixabanapatientsperspective AT abdulrahmanalturaiki comparisonbetweenwarfarinandapixabanapatientsperspective AT mahaalammari comparisonbetweenwarfarinandapixabanapatientsperspective AT khizrasultana comparisonbetweenwarfarinandapixabanapatientsperspective AT leannelai comparisonbetweenwarfarinandapixabanapatientsperspective |
_version_ |
1724841888844873728 |